Product
DCC-2618
Aliases
ripretinib, Ripretinib
Name
QINLOCK
FDA Approved
Yes
2 clinical trials
1 organization
1 drug
3 indications
1 document
Indication
GISTIndication
Advanced Systemic MastocytosisIndication
Advanced CancersDrug
ripretinibClinical trial
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-04-29
Clinical trial
A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer TherapiesStatus: Completed, Estimated PCD: 2019-05-31
Document
DailyMed Label: QINLOCK
Organization
Deciphera Pharmaceuticals, LLC